SYNTARA LIMITED - Announcements

1.96%

2.5¢

Market Cap $40.80M

Healthcare Biotechnology

Syntara Limited is an Australia-based clinical-stage drug development company. The... Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. LATEST: Race Oncology Accelerates Game-Changing Cancer Drug.

Announcements

Filter Results

All Price Sensitive Only

SNT	Letter to shareholders - path forward for amsulostat		01/09/25	205.16KB	Share
SNT	2025 Corporate Governance Statement		28/08/25	213.14KB	Share
SNT	Appendix 4G Key to Disclosures		28/08/25	307.79KB	Share
SNT	Annual Report to shareholders		28/08/25	2.16MB	Share
SNT	Preliminary Final Report	PRICE SENSITIVE	28/08/25	2.21MB	Share
SNT	Application for quotation of securities - SNT		28/08/25	15.71KB	Share
SNT	TechKnow Investor Presentation		19/08/25	1.05MB	Share
SNT	FDA guidance webinar		11/08/25	107.92KB	Share
SNT	Guidance from FDA on amsulostat clinical progression	PRICE SENSITIVE	11/08/25	160.32KB	Share
SNT	Application for quotation of securities - SNT		08/08/25	15.7KB	Share
SNT	Reinstatement to Quotation	PRICE SENSITIVE	04/08/25	86.57KB	Share
SNT	Proposed issue of securities to the CEO		04/08/25	114.82KB	Share
SNT	Notification regarding unquoted securities - SNT		04/08/25	17.74KB	Share
SNT	Quarterly update webinar presentation		01/08/25	390.52KB	Share
SNT	Suspension from Quotation	PRICE SENSITIVE	01/08/25	430.17KB	Share
SNT	Appendix 4C quarterly webinar		01/08/25	129.12KB	Share
SNT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	01/08/25	156.1KB	Share
SNT	Application for quotation of securities - SNT		30/07/25	16.11KB	Share
SNT	Quarterly Shareholder Report	PRICE SENSITIVE	30/07/25	230.71KB	Share
SNT	First participant dosed in SNT-9465 Phase 1a/b trial		29/07/25	183.8KB	Share
SNT	Initiation of Phase 1b/2 AZALOX clinical trial of amsulostat		18/07/25	171.27KB	Share
SNT	First patient dosed in SATELLITE Phase 1c for keloid scars		15/07/25	197.82KB	Share
SNT	WHO grants official INN for SNT-5505 - amsulostat		08/07/25	130.46KB	Share
SNT	Proposed issue of securities to the CEO		02/07/25	91.88KB	Share
SNT	Notification regarding unquoted securities - SNT		02/07/25	16.74KB	Share
SNT	Application for quotation of securities - SNT		01/07/25	16.1KB	Share
SNT	Ceasing to be a substantial holder		23/06/25	125.88KB	Share
SNT	Application for quotation of securities - SNT		16/06/25	16.1KB	Share
SNT	EHA 2025 SNT-5505 Interim Data Webinar Presentation		13/06/25	4.98MB	Share
SNT	New positive interim data in Phase 2 study of SNT-5505	PRICE SENSITIVE	13/06/25	232.17KB	Share
SNT	SNT-5505 interim Phase 2 data webinar		13/06/25	150.06KB	Share
SNT	Application for quotation of securities - SNT		10/06/25	15.69KB	Share
SNT	SNT-5505 awarded US FDA Fast Track designation	PRICE SENSITIVE	10/06/25	192.5KB	Share
SNT	Change in substantial holding		26/05/25	572.36KB	Share
SNT	Change in substantial holding		22/05/25	193.52KB	Share
SNT	Investor Presentation		07/05/25	1.11MB	Share
SNT	March Quarter Shareholder Update Presentation		01/05/25	509.7KB	Share
SNT	Appendix 4C quarterly webinar		30/04/25	175.94KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	30/04/25	214.25KB	Share
SNT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	156.68KB	Share
SNT	Updated SNT-5505 study data to be presented at EHA2025		29/04/25	164.56KB	Share
SNT	Change in substantial holding		24/04/25	182.01KB	Share
SNT	Change in substantial holding		31/03/25	244.36KB	Share
SNT	Notification of cessation of securities - SNT		28/03/25	12.77KB	Share
SNT	Application for quotation of securities - SNT		28/03/25	15.7KB	Share
SNT	Change in substantial holding		24/03/25	161.66KB	Share
SNT	Skin scarring webinar featuring Professor Fiona Wood		18/03/25	176.4KB	Share
SNT	Acceleration of skin scarring program	PRICE SENSITIVE	18/03/25	219KB	Share
SNT	Syntara to present at NWR Virtual Healthcare Conference		14/03/25	174.22KB	Share
SNT	Change of Director's Interest Notice - HDS		14/03/25	255.04KB	Share
SNT	Half Year Report and Appendix 4D	PRICE SENSITIVE	26/02/25	1.43MB	Share
SNT	Notification regarding unquoted securities - SNT		25/02/25	17.54KB	Share
SNT	Change in substantial holding		25/02/25	476.86KB	Share
SNT	Section 708A(5)(e) notice		20/02/25	137.36KB	Share
SNT	Application for quotation of securities - SNT		20/02/25	15.52KB	Share
SNT	SNT drug leads to significant normalisation of skin scarring		18/02/25	565.62KB	Share
SNT	Results of Meeting		17/02/25	142.99KB	Share
SNT	Chair's Address to Shareholders		17/02/25	251.35KB	Share
SNT	Company Secretary Appointment/Resignation		06/02/25	485.78KB	Share
SNT	Investor Presentation Euroz Hartleys Healthcare Forum		04/02/25	1.5MB	Share
SNT	Quarterly Shareholder Report	PRICE SENSITIVE	29/01/25	211.25KB	Share
SNT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/01/25	738.12KB	Share
SNT	Application for quotation of securities - SNT		22/01/25	16.07KB	Share
SNT	Notice of General Meeting/Proxy Form		17/01/25	450.26KB	Share
SNT	Change in substantial holding		23/12/24	527.32KB	Share
SNT	Section 708A(5)(e) notice		19/12/24	516.38KB	Share
SNT	Application for quotation of securities - SNT		19/12/24	15.67KB	Share
SNT	Proposed issue of securities - SNT		12/12/24	16.38KB	Share
SNT	Proposed issue of securities - SNT		12/12/24	16.21KB	Share
SNT	Equity Raising Presentation	PRICE SENSITIVE	12/12/24	1.43MB	Share
SNT	Placement	PRICE SENSITIVE	12/12/24	210.1KB	Share
SNT	Presentation: Phase 2 study of SNT-5505 in myelofibrosis	PRICE SENSITIVE	10/12/24	1.53MB	Share
SNT	Interim data in Phase 2 study of SNT-5505 in myelofibrosis	PRICE SENSITIVE	10/12/24	288.59KB	Share
SNT	Notice of SNT-5505 Interim Phase 2 data webinar		10/12/24	412.4KB	Share
SNT	Trading Halt	PRICE SENSITIVE	10/12/24	878.08KB	Share
SNT	Response to ASX Price Query	PRICE SENSITIVE	04/12/24	1.06MB	Share
SNT	Pause in Trading	PRICE SENSITIVE	04/12/24	115.19KB	Share
SNT	Change in substantial holding		04/12/24	181.01KB	Share
SNT	Change of Director's Interest Notice - GP		29/11/24	532.06KB	Share
SNT	Notification regarding unquoted securities - SNT		29/11/24	15.87KB	Share
SNT	Results of Meeting		28/11/24	469.73KB	Share
SNT	CEO AGM Presentation to Shareholders		28/11/24	1.63MB	Share
SNT	Chair's Address to Shareholders		28/11/24	397.92KB	Share
SNT	Selected for oral presentation at ASH		06/11/24	163.09KB	Share
SNT	Presentation for September Quarterly Shareholder Update		30/10/24	660.74KB	Share
SNT	Quarterly Activities Report	PRICE SENSITIVE	30/10/24	141.52KB	Share
SNT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/24	225.53KB	Share
SNT	Appendix 4C quarterly webinar		29/10/24	112.25KB	Share
SNT	Receipt of R&D Tax Incentive		28/10/24	111.28KB	Share
SNT	Notice of Annual General Meeting/Proxy Form		25/10/24	1.04MB	Share
SNT	Change in substantial holding		21/10/24	152.18KB	Share
SNT	Investor Presentation - Updated		16/10/24	1.17MB	Share
SNT	Application for quotation of securities - SNT		07/10/24	15.66KB	Share
SNT	Date of 2024 AGM and closing date for director nomination		30/09/24	110.84KB	Share
SNT	Application for quotation of securities - SNT		25/09/24	16.08KB	Share
SNT	Change of Director's Interest Notice		24/09/24	229.32KB	Share
SNT	Section 708A(5)(e) notice		24/09/24	126.31KB	Share
SNT	Application for quotation of securities - SNT		24/09/24	15.48KB	Share
SNT	Results of Meeting		20/09/24	166.18KB	Share
SNT	Appendix 4G - Key to Corporate Governance Disclosures		30/08/24	301.41KB	Share

SNT Letter to shareholders - path forward for amsulostat
01/09/25		205.16KB	Share
SNT 2025 Corporate Governance Statement
28/08/25		213.14KB	Share
SNT Appendix 4G Key to Disclosures
28/08/25		307.79KB	Share
SNT Annual Report to shareholders
28/08/25		2.16MB	Share
SNT Preliminary Final Report
28/08/25	PRICE SENSITIVE	2.21MB	Share
SNT Application for quotation of securities - SNT
28/08/25		15.71KB	Share
SNT TechKnow Investor Presentation
19/08/25		1.05MB	Share
SNT FDA guidance webinar
11/08/25		107.92KB	Share
SNT Guidance from FDA on amsulostat clinical progression
11/08/25	PRICE SENSITIVE	160.32KB	Share
SNT Application for quotation of securities - SNT
08/08/25		15.7KB	Share
SNT Reinstatement to Quotation
04/08/25	PRICE SENSITIVE	86.57KB	Share
SNT Proposed issue of securities to the CEO
04/08/25		114.82KB	Share
SNT Notification regarding unquoted securities - SNT
04/08/25		17.74KB	Share
SNT Quarterly update webinar presentation
01/08/25		390.52KB	Share
SNT Suspension from Quotation
01/08/25	PRICE SENSITIVE	430.17KB	Share
SNT Appendix 4C quarterly webinar
01/08/25		129.12KB	Share
SNT Quarterly Appendix 4C Cash Flow Report
01/08/25	PRICE SENSITIVE	156.1KB	Share
SNT Application for quotation of securities - SNT
30/07/25		16.11KB	Share
SNT Quarterly Shareholder Report
30/07/25	PRICE SENSITIVE	230.71KB	Share
SNT First participant dosed in SNT-9465 Phase 1a/b trial
29/07/25		183.8KB	Share
SNT Initiation of Phase 1b/2 AZALOX clinical trial of amsulostat
18/07/25		171.27KB	Share
SNT First patient dosed in SATELLITE Phase 1c for keloid scars
15/07/25		197.82KB	Share
SNT WHO grants official INN for SNT-5505 - amsulostat
08/07/25		130.46KB	Share
SNT Proposed issue of securities to the CEO
02/07/25		91.88KB	Share
SNT Notification regarding unquoted securities - SNT
02/07/25		16.74KB	Share
SNT Application for quotation of securities - SNT
01/07/25		16.1KB	Share
SNT Ceasing to be a substantial holder
23/06/25		125.88KB	Share
SNT Application for quotation of securities - SNT
16/06/25		16.1KB	Share
SNT EHA 2025 SNT-5505 Interim Data Webinar Presentation
13/06/25		4.98MB	Share
SNT New positive interim data in Phase 2 study of SNT-5505
13/06/25	PRICE SENSITIVE	232.17KB	Share
SNT SNT-5505 interim Phase 2 data webinar
13/06/25		150.06KB	Share
SNT Application for quotation of securities - SNT
10/06/25		15.69KB	Share
SNT SNT-5505 awarded US FDA Fast Track designation
10/06/25	PRICE SENSITIVE	192.5KB	Share
SNT Change in substantial holding
26/05/25		572.36KB	Share
SNT Change in substantial holding
22/05/25		193.52KB	Share
SNT Investor Presentation
07/05/25		1.11MB	Share
SNT March Quarter Shareholder Update Presentation
01/05/25		509.7KB	Share
SNT Appendix 4C quarterly webinar
30/04/25		175.94KB	Share
SNT Quarterly Activities Report
30/04/25	PRICE SENSITIVE	214.25KB	Share
SNT Quarterly Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	156.68KB	Share
SNT Updated SNT-5505 study data to be presented at EHA2025
29/04/25		164.56KB	Share
SNT Change in substantial holding
24/04/25		182.01KB	Share
SNT Change in substantial holding
31/03/25		244.36KB	Share
SNT Notification of cessation of securities - SNT
28/03/25		12.77KB	Share
SNT Application for quotation of securities - SNT
28/03/25		15.7KB	Share
SNT Change in substantial holding
24/03/25		161.66KB	Share
SNT Skin scarring webinar featuring Professor Fiona Wood
18/03/25		176.4KB	Share
SNT Acceleration of skin scarring program
18/03/25	PRICE SENSITIVE	219KB	Share
SNT Syntara to present at NWR Virtual Healthcare Conference
14/03/25		174.22KB	Share
SNT Change of Director's Interest Notice - HDS
14/03/25		255.04KB	Share
SNT Half Year Report and Appendix 4D
26/02/25	PRICE SENSITIVE	1.43MB	Share
SNT Notification regarding unquoted securities - SNT
25/02/25		17.54KB	Share
SNT Change in substantial holding
25/02/25		476.86KB	Share
SNT Section 708A(5)(e) notice
20/02/25		137.36KB	Share
SNT Application for quotation of securities - SNT
20/02/25		15.52KB	Share
SNT SNT drug leads to significant normalisation of skin scarring
18/02/25		565.62KB	Share
SNT Results of Meeting
17/02/25		142.99KB	Share
SNT Chair's Address to Shareholders
17/02/25		251.35KB	Share
SNT Company Secretary Appointment/Resignation
06/02/25		485.78KB	Share
SNT Investor Presentation Euroz Hartleys Healthcare Forum
04/02/25		1.5MB	Share
SNT Quarterly Shareholder Report
29/01/25	PRICE SENSITIVE	211.25KB	Share
SNT Quarterly Appendix 4C Cash Flow Report
29/01/25	PRICE SENSITIVE	738.12KB	Share
SNT Application for quotation of securities - SNT
22/01/25		16.07KB	Share
SNT Notice of General Meeting/Proxy Form
17/01/25		450.26KB	Share
SNT Change in substantial holding
23/12/24		527.32KB	Share
SNT Section 708A(5)(e) notice
19/12/24		516.38KB	Share
SNT Application for quotation of securities - SNT
19/12/24		15.67KB	Share
SNT Proposed issue of securities - SNT
12/12/24		16.38KB	Share
SNT Proposed issue of securities - SNT
12/12/24		16.21KB	Share
SNT Equity Raising Presentation
12/12/24	PRICE SENSITIVE	1.43MB	Share
SNT Placement
12/12/24	PRICE SENSITIVE	210.1KB	Share
SNT Presentation: Phase 2 study of SNT-5505 in myelofibrosis
10/12/24	PRICE SENSITIVE	1.53MB	Share
SNT Interim data in Phase 2 study of SNT-5505 in myelofibrosis
10/12/24	PRICE SENSITIVE	288.59KB	Share
SNT Notice of SNT-5505 Interim Phase 2 data webinar
10/12/24		412.4KB	Share
SNT Trading Halt
10/12/24	PRICE SENSITIVE	878.08KB	Share
SNT Response to ASX Price Query
04/12/24	PRICE SENSITIVE	1.06MB	Share
SNT Pause in Trading
04/12/24	PRICE SENSITIVE	115.19KB	Share
SNT Change in substantial holding
04/12/24		181.01KB	Share
SNT Change of Director's Interest Notice - GP
29/11/24		532.06KB	Share
SNT Notification regarding unquoted securities - SNT
29/11/24		15.87KB	Share
SNT Results of Meeting
28/11/24		469.73KB	Share
SNT CEO AGM Presentation to Shareholders
28/11/24		1.63MB	Share
SNT Chair's Address to Shareholders
28/11/24		397.92KB	Share
SNT Selected for oral presentation at ASH
06/11/24		163.09KB	Share
SNT Presentation for September Quarterly Shareholder Update
30/10/24		660.74KB	Share
SNT Quarterly Activities Report
30/10/24	PRICE SENSITIVE	141.52KB	Share
SNT Quarterly Appendix 4C Cash Flow Report
30/10/24	PRICE SENSITIVE	225.53KB	Share
SNT Appendix 4C quarterly webinar
29/10/24		112.25KB	Share
SNT Receipt of R&D Tax Incentive
28/10/24		111.28KB	Share
SNT Notice of Annual General Meeting/Proxy Form
25/10/24		1.04MB	Share
SNT Change in substantial holding
21/10/24		152.18KB	Share
SNT Investor Presentation - Updated
16/10/24		1.17MB	Share
SNT Application for quotation of securities - SNT
07/10/24		15.66KB	Share
SNT Date of 2024 AGM and closing date for director nomination
30/09/24		110.84KB	Share
SNT Application for quotation of securities - SNT
25/09/24		16.08KB	Share
SNT Change of Director's Interest Notice
24/09/24		229.32KB	Share
SNT Section 708A(5)(e) notice
24/09/24		126.31KB	Share
SNT Application for quotation of securities - SNT
24/09/24		15.48KB	Share
SNT Results of Meeting
20/09/24		166.18KB	Share
SNT Appendix 4G - Key to Corporate Governance Disclosures
30/08/24		301.41KB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 2.5¢		Change -0.001(1.96%)		Mkt cap ! $40.80M

Open	High	Low	Value	Volume
2.5¢	2.5¢	2.4¢	$147.7K	5.911M

Buyers (Bids)

No.	Vol.	Price($)
17	1626571	2.4¢

Sellers (Offers)

Price($)	Vol.	No.
2.5¢	311363	2

View Market Depth

No.	Vol.	Price($)
16	1476571	0.024
8	1601649	0.023
2	244000	0.022
2	85000	0.021
9	699545	0.020

Price($)	Vol.	No.
0.025	311363	2
0.026	5040723	8
0.027	2090235	7
0.028	1256484	5
0.029	1158966	7

Last trade - 16.10pm 05/09/2025 (20 minute delay)

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories